Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
The authors report on the preliminary results of an ongoing phase II trial whereby the combination of the new DNA hypomethylating agent, 5-Aza-deoxycytidine (DAC), plus daunorubicin was given as first-line induction therapy to non-pretreated patients with acute myeloid leukemia (except FAB M3). DAC was given as a 4-h intravenous infusion at the dose of 90 mg/m2 daily from days 1-5, while daunorubicin was administered at the dose of 50 mg/m2 on days 1-3. A maximum of two courses were given to the patients with an interval of 4-6 weeks. Up to now, eight patients were accrued, of those six were evaluable for toxicity and response. The main toxic effects were bone marrow suppression, mucositis, nausea and vomiting, and alopecia. All six patients achieved a complete remission after one (five cases) or two (one case) courses. The trial is open for patient accrual.